Next IDPH Update to be Issued July 14
Following today’s update, IDPH is shifting to providing routine updates on COVID-19 data on a monthly basis, with the next one scheduled for July 14.
“It is almost one month since the end of the COVID-19 public health emergency, and I am happy to report that Illinois continues to see low COVID-19 hospitalization rates in every corner of the state,” IDPH Director Dr. Sameer Vohra said. “The Department continues to closely review and monitor COVID-19 data, focusing our efforts on protecting the health of Illinoisians most vulnerable to serious illness.”
Under the CDC’s new surveillance system, counties are ranked at a low level if hospital admissions are below 10 per 100,000 population for a seven-day period; at medium level between 10 and 20 admissions per 100,000; and at high level if admissions are greater than 20 per 100,000.
Both IDPH and the Illinois Department on Aging have endorsed recommendations earlier this month by the FDA and CDC for an optional additional updated bivalent vaccine dose for adults 65 and older and optional additional doses for people who are immunocompromised. The bivalent booster is designed to offer better protection against newer strains of the virus.
On April 19, the CDC recommended a second bivalent booster for those who are 65 and older if it has been at least four months since their first bivalent booster. For those who are immunocompromised, they are eligible for a second bivalent booster if it has been at least two months since their first bivalent booster.
IDPH is helping Illinoisans stay prepared for any future surge of COVID-19 cases by offering 1 million free COVID-19 rapid antigen tests to Illinois residents in all zip codes outside the City of Chicago through a partnership with the Rockefeller Foundation’s public charity, RF Catalytic Capital and its Project ACT (Access COVID Tests) program.
The CDC previously authorized two new bivalent booster vaccines on September 1 that include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an added mRNA component in common between the omicron variant BA.4 and BA.5 lineages to provide better protection against COVID-19 caused by the omicron variant.
Initially, the Moderna COVID-19 Vaccine, Bivalent, was recommended for use as a single booster dose in individuals 18 years of age and older and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, was authorized for use as a single booster dose in individuals 12 years of age and older. On October 12, the CDC authorized the updated COVID-19 vaccines from Pfizer-BioNTech for children ages 5 through 11 years, and from Moderna for children and adolescents ages 6 through 17 years.
On December 9, the CDC expanded its authorization for bivalent boosters to include children aged 6 months to 5 years. On March 14, the FDA expanded its authorization for bivalent boosters to include children aged 6 months to 4 years who had previously completed their entire Pfizer primary series with the monovalent vaccine. For young children, multiple doses of bivalent vaccine continue to be recommended and will vary by age, vaccine, and which vaccines were previously received.
Under the new recommendations, children 6 months through 5 years of age who are unvaccinated may receive a two-dose series of the Moderna bivalent vaccine (6 months through 5 years of age) OR a three-dose series of the Pfizer-BioNTech bivalent vaccine (6 months through 4 years of age). Children who are 5 years of age may receive two doses of the Moderna bivalent vaccine or a single dose of the Pfizer-BioNTech bivalent vaccine.
Children 6 months through 5 years of age who have received one, two or three doses of a monovalent COVID-19 vaccine may receive a bivalent vaccine, but the number of doses that they receive will depend on the vaccine and their vaccination history.